Business Context and Reporting Period
Company: Lineage Cell Therapeutics, Inc. (LCTX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Lineage is a clinical-stage biotechnology company developing allogeneic cell replacement therapies using its proprietary AlloSCOPE manufacturing platform. The company focuses on non-oncology indications including ophthalmology, neurology, and metabolic diseases. All cGMP manufacturing is conducted at a facility in Jerusalem, Israel, operated by its subsidiary Cell Cure Neurosciences Ltd. (CCN).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenues | $14.6 million | $9.5 million |
| Operating Expenses | $51.2 million | $31.0 million |
| Loss from Operations | ($36.6 million) | ($21.5 million) |
| Net Loss | ($63.4 million) | ($18.6 million) |
| Cash, Cash Equivalents & Marketable Securities | $55.8 million | $47.8 million |
| Accumulated Deficit | ($467.0 million) | ($403.5 million) |
| Warrant Liabilities | $43.9 million | $6.2 million |
Note: The 2025 Net Loss includes a non-cash charge of $35.7 million related to the change in fair value of warrant liabilities and a $14.8 million impairment charge on intangible assets.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 53% to $14.6 million, driven primarily by a $5.5 million increase in collaboration revenues. This was due to the achievement of a $5.0 million milestone under the Roche Agreement and $2.5 million in revenue from a new research collaboration with William Demant Invest 2 Aps (WDI).
- Operating Expenses: Increased 65% to $51.2 million. Research and Development (R&D) expenses rose 42% to $17.7 million, reflecting increased investment in OpRegen, ANP1, and new programs. General and Administrative (G&A) expenses remained relatively flat.
- Impairment Charge: The company recorded a $14.8 million non-cash impairment charge in 2025 after abandoning the VAC platform and related intangible assets.
- Warrant Liability Volatility: The fair value of liability-classified warrants increased significantly, resulting in a $35.7 million non-cash loss in 2025 compared to a $2.1 million gain in 2024, driven by fluctuations in the company's stock price.
- Tax Benefit: The company recorded a $5.3 million deferred tax benefit in 2025 due to the release of the valuation allowance on its Israel subsidiary's deferred tax assets, based on sustained profitability in that jurisdiction.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes current cash, cash equivalents, and marketable securities ($55.8 million) are sufficient to fund planned operations for at least twelve months from the filing date. The company expects to continue incurring significant operating losses and will require substantial additional capital to complete clinical development and seek regulatory approval.
Key Developments:
- OpRegen (RG6501): Phase 2a "GAlette" study is ongoing. 36-month data from the Phase 1/2a study showed durable improvement in visual acuity. A $5.0 million milestone was achieved in December 2025.
- OPC1: The "DOSED" clinical study evaluating a novel delivery device for spinal cord injury treated its first chronic SCI patient in July 2025.
- ReSonance (ANP1): Entered a collaboration with WDI in August 2025 to advance preclinical development for hearing loss.
Material Risks:
- Geopolitical Conflict: All manufacturing is located in Jerusalem, Israel. Escalation of conflict in the Middle East poses risks to operations, employee safety, and supply chains.
- Capital Requirements: The company has an accumulated deficit of $467.0 million and relies on equity financings, collaborations, and grants. Failure to raise capital could force delays or suspension of programs.
- Collaboration Dependence: Significant future revenue depends on the success of the collaboration with Roche/Genentech for OpRegen. Roche controls clinical development and commercialization.
- Manufacturing Complexity: Scaling cell therapy manufacturing is complex; the company has limited experience at commercial scale.
Investor Verification Checklist
- Warrant Liability Impact: Verify the sensitivity of the $43.9 million warrant liability to stock price fluctuations and its impact on future non-cash losses.
- Israel Operational Continuity: Assess the specific business continuity plans and insurance coverage regarding the manufacturing facility in Jerusalem amidst regional conflict.
- Roche Collaboration Terms: Review the specific milestones and termination rights in the Roche Agreement, as future revenue is heavily dependent on this partner's execution.
- Cash Burn Rate: Confirm the runway of the $55.8 million cash balance against the projected increase in R&D and G&A expenses for 2026.
- Intangible Asset Valuation: Understand the remaining carrying value of intangible assets ($31.7 million) and the criteria for future impairment testing.